The disqualification list names no device

A regulatory affairs team qualifying a clinical site for an IDE study checks the obvious things: conflicts of interest, financial disclosure, GCP training. FDA runs a narrower, sharper check of its own. A clinical investigator can be formally disqualified, barred from receiving investigational products at all, and the record that tracks it was never built around a device.

One regulation, three centers, one list

21 CFR 812.119 lets the Center for Devices and Radiological Health, the Center for Biologics Evaluation and Research, or the Center for Drug Evaluation and Research disqualify an investigator who has repeatedly or deliberately failed to comply with the investigator obligations in Part 812, the informed-consent rule at Part 50, or the IRB rule at Part 56 — or who has submitted false information to FDA or to the sponsor in a required report. The ground is conduct, not device performance, and the same regulation reaches a device IDE, a drug trial, and a biologic trial identically, because it is one rule shared by all three centers, not a device-specific one.

The process runs before the label does

Disqualification opens with a Notice of Initiation of Disqualification Proceedings and Opportunity to Explain — a NIDPOE letter — and the investigator can answer in writing or ask for an informal conference with the reviewing Center. Accepted, the matter closes there. Not accepted, FDA can move to a formal administrative hearing and, ultimately, a decision. Once disqualified, an investigator is no longer eligible to receive investigational devices, and FDA can require a sponsor to account for what happens to data already collected under their name.

The record has a name field, not a device one

FDA’s Clinical Investigators — Disqualification Proceedings page lists every investigator who is or has been subject to the proceeding, the current status, and the underlying documents — NIDPOEs, hearing notices, and the eventual decision — where FDA has posted them. What it does not carry is a product code, a K-number, a PMA number, or any device identifier at all. The record is keyed to a person, because the finding is about a person’s conduct across however many studies they’ve run, drug or device, not about any one device those studies happened to test.

The finding is about a person’s conduct across however many studies they’ve run. It was never going to fit a field built for a device.

The practice

A device-portfolio watch keyed to product codes, regulation numbers, and clearance numbers — the identifiers a device actually carries — has no way to intersect with a list keyed to a person’s name. Checking an investigator against FDA’s disqualification record is a site-selection step for an IDE study, done by name, before the first subject is enrolled — not a signal any product-code monitor, including this one, was ever built to surface. Per what we monitor and how often, this is regulatory intelligence and method, never regulatory advice about a specific investigator or trial — that determination belongs with the sponsor and its clinical and regulatory team.